Arcagy/ Gineco Group
Clinical trials sponsored by Arcagy/ Gineco Group, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New trial tests drug combo to keep ovarian cancer at bay Results expected Feb 2027 (estimated)
- Weekly chemo boost could help ovarian cancer patients who Don't respond to standard treatment Results expected Jun 2027 (estimated)
- New hope for rare, deadly gynecologic cancers: drug combo trial launches Results expected Jun 2027 (estimated)
-
Can a Hormone-Blocking drug boost chemo against cervical cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding relacorilant—a drug that blocks a stress-related hormone—to the chemotherapy nab-paclitaxel can shrink tumors in people with recurrent or metastatic cervical cancer. Participants have already tried platinum-based chemo and immunotherap…
Phase 2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
Disease control Not yet recruitingThis study tests a new drug, ubamatamab, combined with standard chemotherapy drugs (carboplatin, paclitaxel, and bevacizumab) in 43 people with advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if the combination is safe and can shrink tum…
Phase 1/2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC